{"brief_title": "Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia", "brief_summary": "The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.", "detailed_description": "Patients will take Thalidomide tablets at bedtime daily until remission. The dose will be increased gradually and modified according to side-effects. The drug will be given daily up to the time of complete remission then as long as it is beneficial.", "condition": "Leukemia", "intervention_type": "Drug", "intervention_name": "Thalidomide", "criteria": "Inclusion Criteria: - Diagnosis of refractory or relapsed leukemia: acute leukemia, CML, CLLm and MDS. - Signed informed consent, including patient agreeing to use safe contraceptive methods during the treatment and for at least 4 months after the treatment is completed - Serum creatinine < or = 2.5mg/dL - Serum bilirubin< or = 2.5mg/dL - Negative pregnancy test - Age 18 years or older - Performance status < or = 3 Exclusion Criteria: - Pregnant or lactating women - Concurrent treatment with cytotoxic chemotherapy, or radiation - History of seizures, neurotoxicity, or active CNS disease - Serious infections not controlled by antibiotics", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00083694.xml"}